Detalhe da pesquisa
1.
Longitudinal molecular trajectories of diffuse glioma in adults.
Nature
; 576(7785): 112-120, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31748746
2.
DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis.
Genomics
; 114(2): 110289, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35124175
3.
Physical activity and glioma: a case-control study with follow-up for survival.
Cancer Causes Control
; 33(5): 749-757, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35184245
4.
The role of TP53 gain-of-function mutation in multifocal glioblastoma.
J Neurooncol
; 147(1): 37-47, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32002804
5.
Genome-wide investigation of intragenic DNA methylation identifies ZMIZ1 gene as a prognostic marker in glioblastoma and multiple cancer types.
Int J Cancer
; 145(12): 3425-3435, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31373686
6.
Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis.
J Neurooncol
; 141(1): 1-12, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30392086
7.
Older studies can underestimate prognosis of glioblastoma biomarker in meta-analyses: a meta-epidemiological study for study-level effect in the current literature.
J Neurooncol
; 139(2): 231-238, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29767813
8.
Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.
J Transl Med
; 15(1): 61, 2017 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28314386
9.
Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.
J Neurooncol
; 132(3): 359-372, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28293764
10.
The challenges associated with molecular targeted therapies for glioblastoma.
J Neurooncol
; 127(3): 427-34, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26900075
11.
Incorporation of biomarkers in phase II studies of recurrent glioblastoma.
Tumour Biol
; 36(1): 153-62, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25534238
12.
A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis.
J Biol Chem
; 288(52): 37355-64, 2013 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24265321
13.
The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma.
Tumour Biol
; 35(2): 1459-65, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24068568
14.
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.
Neurooncol Adv
; 5(1): vdad124, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37841696
15.
MMSAT: automated quantification of metabolites in selected reaction monitoring experiments.
Anal Chem
; 84(1): 470-4, 2012 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-22111688
16.
p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells.
J Neurooncol
; 109(1): 35-44, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22528800
17.
Sphingolipid long chain base phosphates can regulate apoptotic-like programmed cell death in plants.
Biochem Biophys Res Commun
; 410(3): 574-80, 2011 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-21683064
18.
TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy.
Cancers (Basel)
; 13(21)2021 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34771529
19.
Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma.
Front Mol Biosci
; 8: 633344, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33996894
20.
PathoFusion: An Open-Source AI Framework for Recognition of Pathomorphological Features and Mapping of Immunohistochemical Data.
Cancers (Basel)
; 13(4)2021 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33557152